Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells with an urgent need for rationally designed therapies to address its notoriously chemo-refractory behavior. The median survival of T-PLL patients is

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	LEUKEMIA 2018-03, Vol.32 (3), p.774-787
Hauptverfasser:	Andersson, E I, Pützer, S, Yadav, B, Dufva, O, Khan, S, He, L, Sellner, L, Schrader, A, Crispatzu, G, Oleś, M, Zhang, H, Adnan-Awad, S, Lagström, S, Bellanger, D, Mpindi, J P, Eldfors, S, Pemovska, T, Pietarinen, P, Lauhio, A, Tomska, K, Cuesta-Mateos, C, Faber, E, Koschmieder, S, Brümmendorf, T H, Kytölä, S, Savolainen, E-R, Siitonen, T, Ellonen, P, Kallioniemi, O, Wennerberg, K, Ding, W, Stern, M-H, Huber, W, Anders, S, Tang, J, Aittokallio, T, Zenz, T, Herling, M, Mustjoki, S
Format:	Artikel
Sprache:	eng
Schlagworte:	38/61 45/23 631/67/1990/283 692/308/575 AKT protein Apoptosis Cancer Research Chemotherapy Clinical trials Critical Care Medicine Cyclin-dependent kinase Cyclin-dependent kinases Drug screening Enzyme inhibitors Gene expression Genetic markers Hematology Histone deacetylase Inhibitors Intensive Internal Medicine Kinases Lesions Leukemia Lymphocytes T Medical research Medicine Medicine & Public Health Mutation Oncology original-article p53 Protein Patients Phase locked systems Rapamycin Sensitivity TOR protein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells with an urgent need for rationally designed therapies to address its notoriously chemo-refractory behavior. The median survival of T-PLL patients is
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2017.252